| 256.38 0.9 (0.35%) | 08-31 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 312.4 | 1-year : | 364.88 |
| Resists | First : | 267.47 | Second : | 312.4 |
| Pivot price | 257.61 |
|||
| Supports | First : | 251.23 | Second : | 241.19 |
| MAs | MA(5) : | 259.7 |
MA(20) : | 254.6 |
| MA(100) : | 231.06 |
MA(250) : | 223.63 |
|
| MACD | MACD : | 2.9 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 54.9 |
D(3) : | 67.4 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 267.47 | Low : | 189.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABBV ] has closed above bottom band by 45.1%. Bollinger Bands are 11% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 258.36 - 259.92 | 259.92 - 261.42 |
| Low: | 248.65 - 250.48 | 250.48 - 252.24 |
| Close: | 253.56 - 256.27 | 256.27 - 258.87 |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Mon, 31 Aug 2026
AbbVie’s Sept. 9 healthcare talk will stream live and stay online - Stock Titan
Sun, 30 Aug 2026
How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks - Barchart.com
Sat, 29 Aug 2026
Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease? - Yahoo Finance UK
Sat, 29 Aug 2026
Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease? - Yahoo Finance
Sat, 29 Aug 2026
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Sat, 29 Aug 2026
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,770 (M) |
| Shares Float | 1,760 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 77.4 (%) |
| Shares Short | 22,550 (K) |
| Shares Short P.Month | 21,900 (K) |
| EPS | 3.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.36 |
| Profit Margin | 9.8 % |
| Operating Margin | 40 % |
| Return on Assets (ttm) | 10.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 10.1 % |
| Gross Profit (p.s.) | 26.48 |
| Sales Per Share | 36.37 |
| EBITDA (p.s.) | 17.37 |
| Qtrly Earnings Growth | 290.3 % |
| Operating Cash Flow | 19,510 (M) |
| Levered Free Cash Flow | 16,870 (M) |
| PE Ratio | 72.21 |
| PEG Ratio | 0.4 |
| Price to Book value | -76.31 |
| Price to Sales | 7.04 |
| Price to Cash Flow | 23.25 |
| Dividend | 1.73 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|